Results 151 to 160 of about 1,129 (187)
Some of the next articles are maybe not open access.
The American Journal of Medicine, 2012
Chlorthalidone has proven efficacy to reduce cardiovascular morbidity and mortality, yet it is infrequently used in practice. This study provides a direct comparison of chlorthalidone with hydrochlorothiazide, each combined with the angiotensin receptor blocker azilsartan medoxomil, on blood pressure reduction and control rates.This is a randomized ...
George L, Bakris +7 more
openaire +2 more sources
Chlorthalidone has proven efficacy to reduce cardiovascular morbidity and mortality, yet it is infrequently used in practice. This study provides a direct comparison of chlorthalidone with hydrochlorothiazide, each combined with the angiotensin receptor blocker azilsartan medoxomil, on blood pressure reduction and control rates.This is a randomized ...
George L, Bakris +7 more
openaire +2 more sources
Azilsartan medoxomil for the treatment of hypertension
Drugs of Today, 2011The use of angiotensin receptor blockers (ARBs) represents a favorable approach for the control of blood pressure in patients with hypertension. Azilsartan medoxomil, a prodrug that undergoes rapid hydrolysis to its active moiety azilsartan, is an angiotensin AT(1) receptor antagonist with promising antihypertensive activity and a good safety profile ...
openaire +2 more sources
Improved Process for Azilsartan Medoxomil: A New Angiotensin Receptor Blocker
Organic Process Research & Development, 2012An improved process for the active pharmaceutical ingredient of a new angiotensin II AT1 receptor antagonist, azilsartan medoxomil, has been developed. The results include reinvestigation of the described process as well as its novel modifications. This new process includes transformation of the CN group into amidoxime moiety by aqueous hydroxylamine ...
Stanislav Rádl +3 more
openaire +1 more source
Expert Opinion on Drug Metabolism & Toxicology, 2013
Azilsartan medoxomil is a newly approved angiotensin-receptor blocker for the management of hypertension. It is a prodrug that is quickly hydrolyzed to the active moiety azilsartan, a potent and highly selective angiotensin-receptor blocker with estimated bioavailability of ∼ 60%. This new agent induces a potent and long-lasting antihypertensive effect.
Angeli F +4 more
openaire +3 more sources
Azilsartan medoxomil is a newly approved angiotensin-receptor blocker for the management of hypertension. It is a prodrug that is quickly hydrolyzed to the active moiety azilsartan, a potent and highly selective angiotensin-receptor blocker with estimated bioavailability of ∼ 60%. This new agent induces a potent and long-lasting antihypertensive effect.
Angeli F +4 more
openaire +3 more sources
Rapid Communications in Mass Spectrometry, 2015
Rationale Azilsartan medoxomil potassium (AZM) is a new antihypertensive drug introduced in the year 2011. The presence of degradation products not only affects the quality, but also the safety aspects of the drug.
Debasish, Swain +4 more
openaire +2 more sources
Rationale Azilsartan medoxomil potassium (AZM) is a new antihypertensive drug introduced in the year 2011. The presence of degradation products not only affects the quality, but also the safety aspects of the drug.
Debasish, Swain +4 more
openaire +2 more sources
Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
Expert Opinion on Pharmacotherapy, 2013Azilsartan medoxomil is the newest angiotensin receptor blocker marketed for the treatment of arterial hypertension. The aim of this article was to review the available evidence about this drug alone or combined with other antihypertensive agents in the treatment of hypertensive population.For this purpose, a search on MEDLINE and EMBASE databases was ...
Vivencio, Barrios, Carlos, Escobar
openaire +2 more sources
Drug Delivery and Translational Research
A prolonged and compromised wound healing process poses a significant clinical challenge, necessitating innovative solutions. This research investigates the potential application of nanotechnology-based formulations, specifically nanofiber (NF) scaffolds, in addressing this issue.
null Alka +9 more
openaire +2 more sources
A prolonged and compromised wound healing process poses a significant clinical challenge, necessitating innovative solutions. This research investigates the potential application of nanotechnology-based formulations, specifically nanofiber (NF) scaffolds, in addressing this issue.
null Alka +9 more
openaire +2 more sources
Azilsartan medoxomil (Edarbi) the eighth ARB.
The Medical letter on drugs and therapeutics, 2011The angiotensin receptor blocker (ARB) azilsartan medoxomil (Edarbi-Takeda) was recently approved by the FDA for oral treatment of hypertension, either alone or combined with other drugs. It is the eighth ARB approved for this indication.
openaire +1 more source
UV Spectrophotometric Method for the estimation of Azilsartan Medoxomil in Bulk Form
Asian Journal of Research in Chemistry, 2018It is simple, sensitive and highly accurate ultraviolet spectrophotometry method has been developed and validated for the determination of Azilsartan medoxomil. It is approved by USFDA for the treatment of hypertension. It is an angiotensin II receptor antagonist. This method is based on the measurement of absorbance of Azilsartan medoxomil solution in
M.N. Gawai, K.S. Surwade, D.G. Phadatare
openaire +1 more source
Integrative oncology: Addressing the global challenges of cancer prevention and treatment
Ca-A Cancer Journal for Clinicians, 2022Jun J Mao,, Msce +2 more
exaly